AU2002340825B2 - HDL for the treatment of stroke and other ischemic conditions - Google Patents

HDL for the treatment of stroke and other ischemic conditions Download PDF

Info

Publication number
AU2002340825B2
AU2002340825B2 AU2002340825A AU2002340825A AU2002340825B2 AU 2002340825 B2 AU2002340825 B2 AU 2002340825B2 AU 2002340825 A AU2002340825 A AU 2002340825A AU 2002340825 A AU2002340825 A AU 2002340825A AU 2002340825 B2 AU2002340825 B2 AU 2002340825B2
Authority
AU
Australia
Prior art keywords
hdl
ischemia
administered
treatment
rhdl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002340825A
Other languages
English (en)
Other versions
AU2002340825A1 (en
Inventor
Alphonse Hubsch
Markus G. Lang
Peter G. Lerch
Roberto Paterno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring AG
Original Assignee
CSL Behring AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01120026A external-priority patent/EP1285662A1/en
Application filed by CSL Behring AG filed Critical CSL Behring AG
Publication of AU2002340825A1 publication Critical patent/AU2002340825A1/en
Application granted granted Critical
Publication of AU2002340825B2 publication Critical patent/AU2002340825B2/en
Assigned to CSL BEHRING AG reassignment CSL BEHRING AG Alteration of Name(s) in Register under S187 Assignors: ZLB BIOPLASMA AG
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
AU2002340825A 2001-08-20 2002-08-20 HDL for the treatment of stroke and other ischemic conditions Ceased AU2002340825B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31360501P 2001-08-20 2001-08-20
US60/313,605 2001-08-20
EP01120026A EP1285662A1 (en) 2001-08-20 2001-08-20 Reconstituted HDL for the treatment of stroke and ischemic conditions
EP01120026.8 2001-08-20
PCT/EP2002/009294 WO2003018047A2 (en) 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions

Publications (2)

Publication Number Publication Date
AU2002340825A1 AU2002340825A1 (en) 2003-06-05
AU2002340825B2 true AU2002340825B2 (en) 2007-07-05

Family

ID=26076691

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002340825A Ceased AU2002340825B2 (en) 2001-08-20 2002-08-20 HDL for the treatment of stroke and other ischemic conditions

Country Status (10)

Country Link
US (2) US20040266660A1 (cg-RX-API-DMAC7.html)
EP (1) EP1425031B8 (cg-RX-API-DMAC7.html)
JP (1) JP4284177B2 (cg-RX-API-DMAC7.html)
AT (1) ATE396736T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002340825B2 (cg-RX-API-DMAC7.html)
CA (1) CA2457840C (cg-RX-API-DMAC7.html)
DE (1) DE60226881D1 (cg-RX-API-DMAC7.html)
ES (1) ES2304452T3 (cg-RX-API-DMAC7.html)
WO (1) WO2003018047A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200401360B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1668645A (zh) * 2002-05-17 2005-09-14 埃斯佩里安医疗公司 治疗缺血再灌注的方法和组合物
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2007000924A1 (ja) * 2005-06-28 2007-01-04 Osaka University プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
US20070110751A1 (en) * 2005-10-25 2007-05-17 Maclellan Robb Compositions and methods for reducing infarct size
AU2007200908B2 (en) * 2007-03-01 2012-08-16 Csl Limited Treatment of endothelial dysfunction in diabetic patients
JP5601750B2 (ja) * 2007-03-01 2014-10-08 シーエスエル、リミテッド 糖尿病患者の内皮機能異常の治療
WO2010151096A1 (en) 2009-06-25 2010-12-29 Tetra, Sia Therapeutic combinations of nicotinic acid and meldonium
WO2011006994A1 (en) 2009-07-16 2011-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Hdl comprising a therapeutic agent and use in therapy
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US20120189612A1 (en) * 2011-01-25 2012-07-26 The Cleveland Clinic Foundation Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy
CN105288589A (zh) 2011-02-07 2016-02-03 塞勒尼斯医疗控股公司 脂蛋白复合物及其制备和用途
EP2688584A4 (en) * 2011-03-25 2015-05-20 Univ Columbia PEGYLATED HUMAN HDL PARTICLES AND METHOD OF PREPARING THEM
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
CA2947127A1 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
ES2984285T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Cargómeros
ES2984286T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Apómeros
WO2021191266A1 (en) 2020-03-25 2021-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolization of hdl for the treatment of lung infections
WO2021209823A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein- based complexes
JP2023543498A (ja) 2020-10-01 2023-10-16 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法
US20230372532A1 (en) * 2020-10-05 2023-11-23 Northwestern University Targeted ph sensitive liposomes
US20240215570A1 (en) 2021-04-15 2024-07-04 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
EP4504233A1 (en) 2022-04-06 2025-02-12 Abionyx Pharma SA Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
AU2023284357A1 (en) 2022-06-10 2025-01-23 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003705A1 (en) * 1999-07-08 2001-01-18 Tularik Inc. Compositions and methods for raising hdl cholesterol levels
WO2001013939A1 (en) * 1999-08-19 2001-03-01 Queen Mary And Westfield College High density lipoprotein against organ dysfunction following haemorrhagic shock

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
AUPQ429399A0 (en) 1999-11-26 1999-12-23 Heart Research Institute, The Oxidized apolipoproteins and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003705A1 (en) * 1999-07-08 2001-01-18 Tularik Inc. Compositions and methods for raising hdl cholesterol levels
WO2001013939A1 (en) * 1999-08-19 2001-03-01 Queen Mary And Westfield College High density lipoprotein against organ dysfunction following haemorrhagic shock

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Artherosclerosis 55:217-223 *
J. Submicroscopic Cyt. & Path. 32:353 *

Also Published As

Publication number Publication date
US7491693B2 (en) 2009-02-17
CA2457840C (en) 2011-10-11
EP1425031A2 (en) 2004-06-09
ES2304452T3 (es) 2008-10-16
HK1064304A1 (en) 2005-01-28
WO2003018047A2 (en) 2003-03-06
US20080108550A1 (en) 2008-05-08
JP4284177B2 (ja) 2009-06-24
DE60226881D1 (de) 2008-07-10
ATE396736T1 (de) 2008-06-15
US20040266660A1 (en) 2004-12-30
CA2457840A1 (en) 2003-03-06
ZA200401360B (en) 2005-08-31
EP1425031B1 (en) 2008-05-28
JP2005501110A (ja) 2005-01-13
WO2003018047A3 (en) 2004-01-29
EP1425031B8 (en) 2008-09-03

Similar Documents

Publication Publication Date Title
US7491693B2 (en) HDL for the treatment of stroke and other ischemic conditions
AU2002340825A1 (en) HDL for the treatment of stroke and other ischemic conditions
KR101668137B1 (ko) 계면 활성 단백질 ｂ (ｓｐ－ｂ) 및 계면 활성 단백질 ｃ (ｓｐ－ｃ)의 유사체를 함유하는 개량된 재구성 계면 활성제 조성물
US6166077A (en) Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1
JPH05506034A (ja) アクチン結合性化合物の療法的使用
CN1248169A (zh) 含有3－环丙基甲氧基－n－(3,5－二氯－4－吡啶基)－4－(二氟甲氧基)苯甲酰胺和肺表面活性剂的治疗ards或irds的组合物
JP2024166198A (ja) 可溶性細胞外マトリックス組成物および血管内送達のための方法
EP0588477A2 (en) Medicinal composition comprising TCF-II
EP1057489B1 (en) Use of midkine family proteins in the treatment of ischemic diseases
HK1064304B (en) Hdl for the treatment of stroke and other ischemic conditions
NO321126B1 (no) Salt av et BPC (Body protection compound) "kroppsbeskyttelsesforbindelse"-peptid, omfattende 8 aminosyrerester, kompatibelt, lagringsstabilt, farmasoytisk preparat, diagnostisk lagringsstabilt preparat, anvendelser og fremgangsmater derav.
WO2003061680A3 (en) Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease
EP1285662A1 (en) Reconstituted HDL for the treatment of stroke and ischemic conditions
TWI311485B (en) Reconstituted hdl for the treatment of stroke and ischemic conditions
WO1998040096A1 (en) Preventives and/or remedies for multiple organ failure
US8106009B2 (en) Pharmaceutical composition for preventing or treating ischemic diseases
WO1995007710A1 (en) Remedy for wound
WO2004096260A1 (ja) 肝障害予防治療剤
WO2025208818A1 (zh) 治疗下肢外周动脉疾病的核酸分子、药物组合物及其应用
HK1026145B (en) A composition for the treatment of irds and ards
Waring Protein and lipid interactions in lung surfactant monolayers
KR20160127017A (ko) 폐내 염증의 완화
AU2003201287A1 (en) Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease
CN1695735A (zh) 人尿激肽原酶在制备脓毒症药物中的应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired